Obstructive sleep apnoea risk profile and the risk of recurrence of atrial fibrillation after catheter ablation

Obstructive sleep apnoea risk profile and the risk of recurrence of atrial fibrillation after catheter ablation
复制标题

阻塞性睡眠呼吸暂停风险概况和导管消融后心房颤动复发的风险。

DOI:
10.1093/europace/eun315
复制
发表时间:
2009-01-01
期刊:
影响因子:
6.1
通讯作者:
Ma, Chang-Sheng
Ma, Chang-Sheng
中科院分区:
医学2区
文献类型:
--
作者:
Tang, Ri-Bo;Dong, Jian-Zeng;Ma, Chang-Sheng

文献摘要

被引文献

相似文献

为了解阻塞性睡眠呼吸暂停(OSA)对阵发性房颤(AF)导管消融术后复发的影响,对178例接受指标性环肺静脉(PV)隔离治疗的阵发性房颤患者进行前瞻性研究。采用柏林问卷将OSA患者分为高危(HR组)和低危(LR组)两组。在178例患者中,HR组104例(58.4%),LR组74例(41.6%)。平均随访344+/-137(91-572)天,44例(24.7%)复发,HR组(25.0%)和LR组(24.3%)复发率差异无统计学意义(P=0.855)。COX分析显示,PV隔离是唯一独立的复发预测因素(风险比为5.11,95%可信区间为1.42~18.47,P=0.013)。HR组和LR组的并发症发生率分别为2.9%和1.9%,差异无统计学意义(P=0.729)。不同危险因素的阻塞性睡眠呼吸暂停患者的复发率和并发症发生率无显著差异。OSA的存在不应降低阵发性房颤患者选择消融手术的决定阈值。
The aim of this study was to identify the impact of obstructive sleep apnoea (OSA) on recurrence after catheter ablation of paroxysmal atrial fibrillation (AF).One hundred and seventy-eight consecutive patients with paroxysmal AF who underwent index circumferential pulmonary vein (PV) isolation were prospectively enrolled. The patients were divided into high risk (HR group) and low risk (LR group) for OSA group with Berlin questionnaire. Of the 178 patients, 104 (58.4%) were in the HR group and 74 (41.6%) were in the LR group. After a mean follow-up of 344 +/- 137 (91-572) days, 44 patients (24.7%) experienced recurrence, and the recurrence rate did not differ between the HR (25.0%) and LR groups (24.3%, P = 0.855). Cox analysis revealed that PV isolation was the only independent predictor of recurrence (hazard ratio 5.11, 95% confidence interval 1.42-18.47, P = 0.013). There was no significant difference in the incidence of complications between the HR and LR groups (2.9 vs. 1.9%, P = 0.729).The recurrence rate and incidence of complications did not differ in patients with different risk profiles for OSA. The presence of OSA should not lower the decision threshold to choose an ablative procedure in paroxysmal AF.